Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated May 25, 2026, titled "Press Release on the audited (standalone and consolidated) financial results for the quarter and year ended March 31, 2026".
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 0.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics reported its highest-ever PAT of ₹1,014 million in FY2026, representing a 31% year-on-year growth, on consolidated revenue of ₹7,728 million. The profit includes a fair valuation gain of ₹221.75 million from investment in Apulka Healthcare Private Limited. Diluted EPS stood at ₹30.88, up 31%. Operating cash flows improved significantly to ₹1,431 million from ₹873 million in FY2025, a 64% jump reflecting structural improvements in collections and working capital management. The Board recommended a final dividend of ₹2 per share. The retail diagnostics vertical (Krsnaa Retail Private Limited) achieved an 8x revenue jump and expanded to 3,500 locations across 5 states within just 12 months.
Strong financial performance with record PAT and robust cash flow generation signals operational strength and improving business quality. The 31% PAT growth and 64% operating cash flow improvement are positive indicators for shareholders, though the fair valuation gain in PAT partially inflates the headline growth figure.